Overview

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

Phase:

Phase 2

Details

Lead Sponsor:

Mirum Pharmaceuticals, Inc.

Treatments:

Volixibat